Candesartan cilexetil: In children and adolescents aged 1 to <17 years with hypertension

American Journal of Cardiovascular Drugs

Volumn 10, Issue 5, 2010, Pages 335-342

  Hoy, Sheridan M ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Adolescents; Children; Hypertension; Infants

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; NIFEDIPINE; ORAL CONTRACEPTIVE AGENT; PLACEBO; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN; WARFARIN;

ADOLESCENT; ADULT; ALBUMINURIA; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; BODY WEIGHT; BRONCHOPNEUMONIA; CHILD; CLINICAL TRIAL; COUGHING; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG RESPONSE; DRUG TOLERANCE; FEVER; GASTROENTERITIS; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; LYMPHEDEMA; MONOTHERAPY; PHARYNGITIS; PRIORITY JOURNAL; REVIEW; RHINITIS; RHINOPHARYNGITIS; SORE THROAT; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADOLESCENT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; CHILD; CHILD, PRESCHOOL; HUMANS; HYPERTENSION; INFANT; TETRAZOLES;

EID: 77957311843     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11206300-000000000-00000     Document Type: Review

References (16)

1. Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and adolescents. JAMA 2007 Aug; 298(8):874-9
2. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004 Aug; 114 (2 Suppl. 4th Report): 555-76 (Pubitemid 39006657)
3. Lurbe E, Cifkova R, Cruickshank JK, et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens 2009 Sep; 27(9):1719-42
4. Flynn JT. Pediatric hypertension: recent trends and accomplishments, future challenges. Am J Hypertens 2008 Jun; 21(6):605-12
5. AstraZeneca. Atacand® (candesartan cilexetil) tablets: prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2009/020838s031lblpdf [Accessed 2010 Jul. 2]
6. McClellan KJ, Goa KL. Candesartan cilexetil: a review of its use in essential hypertension. Drugs 1998 Nov; 56(5):847-69 (Pubitemid 28525942)
7. Easthope SE, Jarvis B. Candesartan cilexetil: an update of its use in essential hypertension. Drugs 2002;62(8):1253-87 (Pubitemid 34591101)
8. Fenton C, Scott LJ. Candesartan cilexetil : a review of its use in the management of chronic heart failure. Drugs 2005;65(4):537-58 (Pubitemid 40476088)
9. Melian EB, Jarvis B. Candesartan cilexetil plushydrochlorothiazide combination: a review of its use in hypertension. Drugs 2002;62(5):787-816 (Pubitemid 34494023)
10. Trachtman H, Hainer JW, Sugg J, et al. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens 2008 Oct; 10(10):743-50
11. Schaefer F, Van De Walle J, Zurowska A, et al. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens 2010 May; 28(5):1083-90
12. AstraZeneca. An open-label extension study of candesartan cilexetil in hypertensive pediatric subjects ages 1 to <11 years: a long-term study [online]. Available from URL: http://www.astrazenecaclinicaltrials.com/drug- products/drug products/?itemId=8592674 [Accessed 2010 Sep. 14]
13. AstraZeneca. Atacand dose range finding study in pediatric subjects 6 to <17 years of age. [ClinicalTrials.gov identifier NCT00244634]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Jul. 6]
14. AstraZeneca. Atacand dose ranging in hypertensive pediatric subjects 1 year to less than 6 years of age. [ClinicalTrials.gov identifier NCT00244621]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Jul. 6]
15. AstraZeneca. Study to characterize the long-term clinical experience of Atacand in hypertensive children ages 1 to <11 years (HIP). [ClinicalTrials.gov identifier NCT00690612]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Jul. 6]
16. Meier CM, Simonetti GD, Ghiglia S, et al. Palatability of angiotensin II antagonists among nephropathic children. Br J Clin Pharmacol 2007 May; 63(5):628-31 (Pubitemid 46632576)